drug

voclosporin

Marketedupdated 2mo ago

by $AUPH Aurinia Pharmaceuticals Inc.

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for lupus nephritis and immune system disease and 9 investigational indications.

all catalysts(3)

approval · 3

Jan 22, 2021

approval

5y ago

LUPKYNIS (VOCLOSPORIN) — FDA approval

LUPKYNIS (VOCLOSPORIN) — FDA approval

LUPKYNIS (VOCLOSPORIN) — FDA approval

voclosporin

→

News(0)

no news has mentioned this drug yet

brand

Lupkynis

generic

voclosporin

MOA

12.1 Mechanism of Action LUPKYNIS is a calcineurin-inhibitor immunosuppressant. The mechanism of voclosporin suppression of calcineurin has not been fully established. Activation of lymphocytes involves an increase in intracellular calcium concentrations that bind to the calcineurin regulatory site and activate calmodulin binding catalytic subunit and through dephosphorylation activates the transcription factor, Nuclear Factor of Activated T-Cell Cytoplasmic (NFATc). The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Studies in animal models also support a non-immunological role for calcineurin inhibition in kidney function to stabilize actin cytoskeleton and stress fibers in podocytes leading to increased podocyte integrity in glomeruli.

indication

Lupus Nephritis

phase

marketed

voclosporin

all catalysts(3)

News(0)

Patent cliff

patents (3)

FDA exclusivities (1)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying voclosporin